This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
ClinicalTrials.gov Identifier:
NCT00340899
First received: June 19, 2006
Last updated: June 30, 2017
Last verified: April 7, 2017
June 19, 2006
June 30, 2017
December 4, 1997
Not Provided
  • Preterm delivery [ Time Frame: Ongoing ]
  • Preeclampsia [ Time Frame: Ongoing ]
  • Intrauterine growth restriction [ Time Frame: Ongoing ]
Not Provided
Complete list of historical versions of study NCT00340899 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study
Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Restriction: A Longitudinal Study
Preterm delivery, preeclampsia and intrauterine growth restriction are leading causes of perinatal morbidity and mortality. Efforts to treat these syndromes have not been effective, most likely becuase these obstetric complications are the clinical expression of adaptive mechanisms of host defense developed in response to pathologic insults. Since the ultimate pathologic basis of disease is unclear, therapy for these syndromes has been largely directed at symptoms, which appear late in the development of the disease. The main purpose of this study is to perform an early and comprehensive exploration of maternal and fetal factors that predict the subsequent develpment of these obstetrice complications, so that early medical interventions may be tested in patients at high and low risk for adverse perinatal outcome.
Preterm delivery, preeclampsia and intrauterine growth restriction are leading causes of perinatal morbidity and mortality. Efforts to treat these syndromes have not been effective, most likely because these obstetric complications are the clinical expression of adaptive mechanisms of host defense developed in response to pathologic insults. Since the ultimate pathologic basis of disease is unclear, therapy for these syndromes has been largely directed at symptoms, which appear late in the development of the disease. The main purpose of this study is to perform an early and comprehensive exploration of maternal and fetal factors that predict the subsequent development of these obstetric complications, so that early medical interventions may be tested in patients at high and low risk for adverse perinatal outcome.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Prenatal Care
  • Premature Birth
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
27778
Not Provided
Not Provided
  • INCLUSION CRITERIA:
  • Gestational age between 6 and 22 weeks for the first visit based on the patient s last menstrual period as reported by the patient.
  • High risk group: presence of specific risk factors for preterm delivery, pregnancy-induced hypertension or intrauterine growth retardation.
  • Low risk group: normal pregnancy with no risk factors for preterm delivery, pregnancy-induced hypertension or intrauterine growth retardation (control population, selected between 6 and 22 weeks at the prenatal care clinic). The rationale to include this group is that 50-70% of preterm deliveries occur in patients without risk factors for preterm birth.
  • Consent to participate in the study.
  • Patient should be able to attend each Perinatal Research Center for prenatal care and participation in this study.

EXCLUSION CRITERIA:

  • Preterm labor, preterm PROM, preeclampsia or impaired fetal growth at the time of recruitment.
  • Any maternal or fetal condition that requires termination of pregnancy.
  • Known major fetal anomaly or fetal demise.
  • Active vaginal bleeding.
  • Multifetal pregnancy with greater than or equal to 3 fetuses.
  • Serious medical illness (renal insufficiency, congestive heart disease, chronic respiratory insufficiency, etc).
  • Severe chronic hypertension (requiring medication).
  • Asthma requiring systemic steroids.
  • Patient requiring anti-platelet or non-steroidal anti-inflammatory drugs.
  • Active hepatitis.
  • Lack of consent.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
Australia,   Chile,   Italy,   Korea, Republic of
 
NCT00340899
999997067
OH97-CH-N067
Not Provided
Not Provided
Not Provided
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not Provided
Principal Investigator: Roberto Romero, M.D. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institutes of Health Clinical Center (CC)
April 7, 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP